Head-to-head comparisons of enhanced CT, <SUP>68</SUP>Ga-PSMA-11 PET/CT and <SUP>18</SUP>F-FDG PET/CT in identifying adverse pathology of clear-cell renal cell carcinoma: a prospective study
Shao-Hao Chen,Bo-Han Lin,Shao-Ming Chen,Qian-Ren-Shun Qiu,Zhong-Tian Ruan,Ze-Jia Chen,Yong Wei,Qing-Shui Zheng,Xue-Yi Xue,Wei-Bing Miao,Ning Xu
DOI: https://doi.org/10.1590/S1677-5538.IBJU.2023.0312
2023-01-01
International braz j urol
Abstract:Objectives: Accurate preoperative prediction of adverse pathology is crucial for treatment planning of renal cell carcinoma (RCC). Previous studies have emphasized the potential of prostate-specific membrane antigen positron emission tomography / computed tomography (PSMA PET/CT) in differentiating between benign and malignant localized renal tumors. However, there is a scarcity of case reports elucidating the identification of aggressive pathological features using PET/CT. Our study was designed to prospectively compare the diagnostic value of enhanced CT, Ga-68-PSMA-11 and F-18-fluorodeoxyglucose (F-18-FDG) PET/CT in clear-cell renal cell carcinoma (ccRCC) with necrosis or sarcomatoid or rhabdoid differentiation. Materials and Methods: A prospective case series of patients with a newly diagnosed renal mass who underwent enhanced CT, Ga-68-PSMA-11 and F-18-FDG PET/CT within 30 days prior to nephrectomy was included. Complete preoperative and postoperative clinicopathological data were recorded. Patients who received neoadjuvant targeted therapy, declined enhanced CT or PET/CT scanning, refused surgical treatment or had non-ccRCC pathological indications were excluded. Radiological parameters were compared within subgroups of pathological characteristics. Bonferroni corrections were used to adjust for multiple testing and statistical significance was set at a p-value less than 0.017. Results: Seventy-two patients were available for the final analysis. Enhanced CT demonstrated poor performance in identifying necrosis, sarcomatoid or rhabdoid differentiation and adverse pathology (all P > 0.05). The maximum standardized uptake value (SUVmax) of Ga-68-PSMA-11 PET/CT was more effective than F-18-FDG PET/CT in identifying tumor necrosis and adverse pathology, with an area under the curve (AUC) of 0.85 (cutoff value=25.26, p<0.001; Delong test z=2.709, p=0.007) for tumor necrosis and AUC of 0.90 (cutoff value=25.26, p<0.001; Delong test z=3.433, p<0.001) for adverse pathology. However, no significant statistical difference was found between (68)GaPSMA-11 and F-18-FDG PET/CT in predicting sarcomatoid or rhabdoid feature (AUC of 0.91 vs.0.75, Delong test z=1.998, p=0.046). Subgroup analyses based on age, sex, tumor location, maximal diameter, stage and WHO/ISUP grade demonstrated that (68)GaPSMA-11 PET/CT SUVmax had a significant predictive value for adverse pathology. Enhanced CT value and SUVmax demonstrated strong reliability [intraclass correlation coefficient (ICC) > 0.80], indicating a robust correlation. Conclusions: Ga-68-PSMA-11 PET/CT demonstrates distinct advantages in identifying aggressive pathological features of primary ccRCC when compared to enhanced CT and F-18-FDG PET/CT. Further research and assessment are warranted to fully establish the clinical utility of Ga-68-PSMA-11 PET/CT in ccRCC.